About
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.
Current Value
$9.361 Year Return
Current Value
$9.361 Year Return
Key Details
Market Cap
$144.37M
P/E Ratio
-2.1
1Y Stock Return
-77.32%
1Y Revenue Growth
-
Dividend Yield
0.00%
Price to Book
0.5
Stock's related to NGNE
The stocks that are correlated to NGNE - Neurogene, Inc. are ZNTL, SNDX, IMNM, IRON, ZYME
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 42.70% | $92.28M | -91.61% | 0.00% | |
| 39.43% | $1.07B | -44.92% | 0.00% | |
 IMNMImmunome, Inc. | 39.11% | $542.57M | -69.20% | 0.00% |
| 38.22% | $1.58B | +55.15% | 0.00% | |
 ZYMEZymeworks, Inc. | 37.03% | $824.23M | +21.64% | 0.00% |
| 34.77% | $1.36B | -62.39% | 0.00% | |
| 34.55% | $1.11B | -17.36% | 0.00% | |
| 33.96% | $545.16M | -31.38% | 0.00% | |
| 33.95% | $562.78M | +0.98% | 0.00% | |
| 33.44% | $1.03B | -22.49% | 0.00% | |
| 33.28% | $2.08B | -40.69% | 0.00% | |
| 33.21% | $1.55B | -40.65% | 0.00% | |
 GSATGlobalstar, Inc. | 32.90% | $2.48B | -1.50% | 0.00% |
| 31.82% | $758.88M | -58.48% | 0.00% | |
| 31.52% | $1.64B | -43.30% | 0.00% | |
| 31.05% | $607.65M | +7.49% | 0.00% | |
 ACLXArcellx, Inc. | 30.75% | $3.43B | +0.69% | 0.00% |
| 30.25% | $14.93B | -29.60% | 6.35% | |
| 30.21% | $592.86M | -77.74% | 0.00% | |
| 30.17% | $3.38B | +18.62% | 0.00% | |
ETF's related to NGNE
The ETFs that are correlated to NGNE - Neurogene, Inc. are XBI, IBB, GNOM, CPRJ, IWC
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 37.95% | $5.06B | 0.35% | |
| 36.43% | $5.70B | 0.45% | |
| 35.69% | $48.48M | 0.5% | |
| 33.40% | $48.65M | 0.69% | |
| 30.85% | $809.63M | 0.6% | |
| 30.43% | $112.39M | 0% | |
| 30.31% | $362.92M | 0.35% | |
| 28.46% | $229.13M | 0.58% | |
| 27.77% | $987.53M | 0.75% | |
| 27.42% | $10.93B | 0.24% | |
| 27.15% | $63.84B | 0.19% | |
| 27.04% | $11.24B | 0.07% | |
| 26.65% | $110.09M | 0.6% | |
| 25.96% | $294.73M | 0% | |
| 25.94% | $11.04B | 0.24% | |
| 25.73% | $16.19B | 0.04% | |
| 25.66% | $1.12B | 0.31% | |
| 25.55% | $1.09B | 0.56% | |
| 25.35% | $320.39M | 0.79% | |
| 24.95% | $85.91M | 0.45% | |
News
Finnhub
NEW YORK - Neurogene Inc. , a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced a peer-reviewed...
Yahoo
NEW YORK, April 02, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced a peer-reviewed publication on its EXACT™ transgene regulation technology. The preclinical studies demonstrate EXACT’s ability to regulate gene therapy expression to a tolerable and therapeutic level, including in preclinical models of Rett syndrome. These data, published in Science Tran
Yahoo
Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit
Yahoo
NEW YORK, March 24, 2025--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2024 financial results and highlighted recent corporate updates.
Finnhub
Corporate Presentation March 2025 Neurogene is a Differentiated Clinical-Stage Company Utilizing Technology to Treat Complex...
Finnhub
Neurogene Inc: * NEUROGENE INC: FILES FOR MIXED SHELF OFFERING OF UP TO$300MILLION - SEC FILINGSource text:Further company coverage: ...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds